Neuland Laboratories Limited

Equities

NEULANDLAB

INE794A01010

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:49 2024-04-26 am EDT 5-day change 1st Jan Change
6,984 INR -1.93% Intraday chart for Neuland Laboratories Limited -5.22% +32.08%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes RE
Neuland Laboratories Limited Announces Resignation of P.V. Maiya as Director CI
Neuland Laboratories Names Chief Quality Officer MT
Neuland Laboratories Limited Announces Appointment of Ashutosh Kumar Sinha as Chief Quality Officer CI
Transcript : Neuland Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024
Neuland Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Neuland Laboratories Names Chief Scientific Officer MT
Neuland Laboratories Limited Announces the Appointment of Dr. Sharadsrikar V.Kotturi as Chief Scientific Officer CI
Transcript : Neuland Laboratories Limited, Q2 2024 Earnings Call, Nov 07, 2023
Neuland Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Neuland Laboratories Limited Announces Resignation of Humayun Dhanrajgir as Independent Director CI
Transcript : Neuland Laboratories Limited, Q1 2024 Earnings Call, Aug 03, 2023
Neuland Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Neuland Laboratories Limited Approves Final Dividend for the Financial Year 2022-23 CI
Neuland Laboratories Limited Announces Director Appointments CI
Transcript : Neuland Laboratories Limited, Q4 2023 Earnings Call, May 11, 2023
Neuland Laboratories' Consolidated Net Profit Soars in Fiscal Q4 MT
Neuland Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Neuland Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Neuland Laboratories Limited Recommends Final Dividend for the Financial Year 2022-23 CI
Crisil Raises Neuland Laboratories Rating to A; Outlook Stable MT
Transcript : Neuland Laboratories Limited, Q3 2023 Earnings Call, Feb 14, 2023
Neuland Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Neuland Laboratories to Sell Company Land in Hyderabad, India for $14 Million MT
Neuland Laboratories Appoints CFO MT
Chart Neuland Laboratories Limited
More charts
Neuland Laboratories Limited is an India-based company, which is engaged in manufacturing and selling of bulk drugs. The Company caters to both domestic and international markets. It manufactures active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs. The Company provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company operates through a single segment, manufacture of active pharmaceutical ingredients and allied services. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6,984 INR
Average target price
8,300 INR
Spread / Average Target
+18.85%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NEULANDLAB Stock
  4. News Neuland Laboratories Limited
  5. Neuland Laboratories' Consolidated Net Profit Soars in Fiscal Q4